CTMX FY 2024 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$138M+36.4% YoY

Gross Profit

$138M100.0% margin

Operating Income

$25M18.1% margin

Net Income

$32M23.1% margin

EPS (Diluted)

$0.38

Cash Flow

Operating Cash Flow

-$86M

Free Cash Flow

-$87M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$121M

Total Liabilities

$121M

Stockholders' Equity

-$456,000

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$138M	$101M	+36.4%
Gross Profit	$138M	$101M	+36.4%
Operating Income	$25M	-$6M	+485.5%
Net Income	$32M	-$569,000	+5700.9%